Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Clin Transl Oncol ; 11(6): 387-92, 2009 Jun.
Article de Anglais | MEDLINE | ID: mdl-19531454

RÉSUMÉ

INTRODUCTION: The long-term results of the Spanish Study Protocol SEOP-SO-95 for treatment of localised osteosarcoma of the extremities in children were evaluated. PATIENTS AND METHODS: One hundred consecutive patients under 18 years of age from 22 institutions were enrolled from January 1995 to December 2000. Immunohistochemical expression of p53, HER/erbB-2 and P-glycoprotein were retrospectively studied in 27 patients. Treatment consisted of: preoperative chemotherapy with doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue and ifosfamide for 14 weeks; surgery of primary tumour in week 16; postoperative chemotherapy with the above-mentioned drugs for 25 weeks. RESULTS: With a median follow-up of 124 months (range 84-158 months), 69 patients (69%) were continuously event-free survivors; the 10-year probability of event-free survival (EFS) was 62%. Conservative surgery was performed in 85% of patients. Twenty-six patients had local recurrence or distant relapse. The median time to recurrence/ relapse was 27 months (range 17-93 months). The local recurrence rate was 7% (7 of the 100 patients); 4 had wide surgical margins, 2 marginal and 1 intralesional. Four patients died as a result of chemotherapy-related toxicity and 1 developed a second neoplasia (acute myeloid leukaemia). p53 expression and HER2/erbB-2 expression showed no effect on survival or EFS. CONCLUSIONS: This therapeutic protocol achieved good oncologic and orthopaedic results. We observed a significant treatment-related toxicity.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs osseuses/traitement médicamenteux , Ostéosarcome/traitement médicamenteux , Adolescent , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Tumeurs osseuses/génétique , Tumeurs osseuses/mortalité , Tumeurs osseuses/chirurgie , Traitement médicamenteux adjuvant , Enfant , Enfant d'âge préscolaire , Association thérapeutique , Survie sans rechute , Membres , Femelle , Études de suivi , Gènes MDR , Gènes erbB-2 , Gènes p53 , Humains , Estimation de Kaplan-Meier , Mâle , Traitement néoadjuvant , Récidive tumorale locale/épidémiologie , Seconde tumeur primitive/épidémiologie , Ostéosarcome/génétique , Ostéosarcome/mortalité , Ostéosarcome/chirurgie , Complications postopératoires/induit chimiquement , Complications postopératoires/mortalité , Espagne/épidémiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE